Xenon Pharmaceuticals Inc
XENE41.380USD
+0.990+2.45%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
3.19BValor de mercado
PerdaP/L TTM
Mais detalhes de Xenon Pharmaceuticals Inc Empresa
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Informações de Xenon Pharmaceuticals Inc
Código da empresaXENE
Nome da EmpresaXenon Pharmaceuticals Inc
Data de listagemOct 17, 2014
CEOMortimer (Ian C)
Número de funcionários316
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 17
Endereço3650 Gilmore Way
CidadeVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV5G 4W8
Telefone16044843300
Sitehttps://www.xenon-pharma.com/
Código da empresaXENE
Data de listagemOct 17, 2014
CEOMortimer (Ian C)
Executivos da empresa Xenon Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-3.00%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Elizabeth A. (Betsy) Garofalo, M.D.
Dr. Elizabeth A. (Betsy) Garofalo, M.D.
Independent Director
Independent Director
--
--
Ms. Andrea Marie Difabio, J.D.
Ms. Andrea Marie Difabio, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-3.00%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
Canada
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
Outro
69.17%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
Outro
69.17%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
47.83%
Investment Advisor
34.42%
Hedge Fund
25.98%
Research Firm
1.49%
Sovereign Wealth Fund
1.38%
Private Equity
1.01%
Pension Fund
0.66%
Bank and Trust
0.38%
Individual Investor
0.11%
Participação acionária institucional
Atualizado em: qua, 21 de jan
Atualizado em: qua, 21 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q4
396
86.69M
116.66%
--
2025Q4
467
86.87M
112.42%
-7.01M
2025Q3
446
85.67M
110.86%
-494.45K
2025Q2
418
85.39M
111.27%
+856.94K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
6.25M
8.09%
-150.44K
-2.35%
Sep 30, 2025
Avoro Capital Advisors LLC
5.40M
6.99%
--
--
Sep 30, 2025
Driehaus Capital Management, LLC
4.17M
5.4%
-166.53K
-3.84%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.06M
5.25%
-63.84K
-1.55%
Sep 30, 2025
Janus Henderson Investors
3.94M
5.1%
+366.15K
+10.23%
Sep 30, 2025
Wellington Management Company, LLP
3.61M
4.67%
+1.44M
+65.99%
Sep 30, 2025
Braidwell LP
3.61M
4.67%
--
--
Sep 30, 2025
Capital International Investors
3.18M
4.12%
-56.00
-0.00%
Sep 30, 2025
Commodore Capital LP
2.70M
3.49%
-325.00K
-10.74%
Sep 30, 2025
Polar Capital LLP
2.55M
3.3%
-156.49K
-5.79%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Neuroscience and Healthcare ETF
4.41%
ALPS Medical Breakthroughs ETF
1.35%
Goldman Sachs Future Health Care Equity ETF
1.13%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
0.8%
JPMorgan Fundamental Data Science Small Core ETF
0.57%
JPMorgan Healthcare Leaders ETF
0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.45%
ProShares Ultra Nasdaq Biotechnology
0.42%
Invesco Nasdaq Biotechnology ETF
0.32%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção4.41%
ALPS Medical Breakthroughs ETF
Proporção1.35%
Goldman Sachs Future Health Care Equity ETF
Proporção1.13%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporção0.8%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.57%
JPMorgan Healthcare Leaders ETF
Proporção0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporção0.45%
ProShares Ultra Nasdaq Biotechnology
Proporção0.42%
Invesco Nasdaq Biotechnology ETF
Proporção0.32%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
